| Symbol | VSNPF |
|---|---|
| Name | VISEN PHARMACEUTICALS |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | China Suite 3-108, Floor 3, Building B Hengtai Lixiang Chuangxin Tower |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://www.visenpharma.com/en/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | — |
| Description | Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Companys main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization. Additional info from OTC: |
No news found.